Pages that link to "Q83974098"

The following pages link to Chemotherapy-resistant metastatic breast cancer (Q83974098):

Displaying 30 items.

• Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1 (Q33750756) (← links)
• CIAPIN1 gene silencing enhances chemosensitivity in a drug-resistant animal model in vivo (Q33822138) (← links)
• Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. (Q33827053) (← links)
• Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications (Q33838622) (← links)
• Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer (Q35281792) (← links)
• DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer (Q35434433) (← links)
• Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal (Q35815736) (← links)
• Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line (Q36243013) (← links)
• Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products (Q36273796) (← links)
• Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells (Q36319385) (← links)
• Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6. (Q36545926) (← links)
• Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells (Q36883777) (← links)
• Noninvasive theranostic imaging of HSV1-sr39TK-NTR/GCV-CB1954 dual-prodrug therapy in metastatic lung lesions of MDA-MB-231 triple negative breast cancer in mice (Q38466750) (← links)
• Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer (Q40241837) (← links)
• Nanomedicine applications in the treatment of breast cancer: current state of the art. (Q41483629) (← links)
• Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers (Q41790940) (← links)
• Severe everolimus-induced steatohepatis: a case report (Q43099927) (← links)
• Organotypic culture of breast tumor explants as a multicellular system for the screening of natural compounds with antineoplastic potential (Q43249219) (← links)
• Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. (Q49723815) (← links)
• Post-translational modification of OCT4 in breast cancer tumorigenesis. (Q51418102) (← links)
• Stromal cells in breast cancer as a potential therapeutic target. (Q55016792) (← links)
• Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. (Q55309854) (← links)
• Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance (Q57816590) (← links)
• MiR-591 functions as tumor suppressor in breast cancer by targeting TCF4 and inhibits Hippo-YAP/TAZ signaling pathway (Q64092206) (← links)
• Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft (Q88721921) (← links)
• Curcumin Inhibits the Tumorigenesis of Breast Cancer by Blocking Tafazzin/Yes-Associated Protein Axis (Q90247747) (← links)
• Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer (Q90704765) (← links)
• Insights on CXC chemokine receptor 2 in breast cancer: An emerging target for oncotherapy (Q91584509) (← links)
• Arrestin Domain Containing 3 Reverses Epithelial to Mesenchymal Transition and Chemo-Resistance of TNBC Cells by Up-Regulating Expression of miR-200b (Q91801541) (← links)
• Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer (Q93078802) (← links)